<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00923364</url>
  </required_header>
  <id_info>
    <org_study_id>090096</org_study_id>
    <secondary_id>09-C-0096</secondary_id>
    <nct_id>NCT00923364</nct_id>
    <nct_alias>NCT00884923</nct_alias>
  </id_info>
  <brief_title>Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC</brief_title>
  <official_title>Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients With GATA2 Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  Stem cells are immature blood cells that grow in the bone marrow and produce all of the
           cells needed for normal blood and immunity. Stem cells can be taken from one person
           (donor) and given to another person (recipient) through allogeneic stem cell
           transplantation. Donor stem cells can then replace the recipients stem cells in the bone
           marrow, restoring normal blood production and immunity. Most allogeneic transplants now
           use stem cells collected from the donors blood in a process called peripheral blood stem
           cell transplantation.

        -  Monocytopenia and mycobacterial infection (MonoMAC) is an immunodeficiency disease that
           is characterized by a lack of monocytes, a type of white blood cell, and an increased
           risk of developing mycobacteria infections that may cause tuberculosis.

        -  Allogeneic stem cell transplantation has been used successfully to treat many kinds of
           immune diseases and cancers that develop in blood or immune system cells. Researchers
           have been studying a particular kind of stem cell transplantation that uses lower than
           usual doses of chemotherapy and particular combinations of drugs to improve the results
           of the procedure for patients with blood-related cancers and pre-cancerous conditions.

      Objectives:

        -  To determine the safety and efficacy of reduced-intensity hematopoietic stem cell
           transplants (a particular stem cell transplantation procedure) for treating MonoMAC.

      Eligibility:

        -  Patients 18-60 years of age who have MonoMAC and who have been matched with a suitable
           stem cell donor.

      Design:

        -  Donors and recipients will undergo separate procedures as part of this protocol.

        -  Donors:

        -  National Institutes of Health researchers will take the donor s medical history, perform
           a physical exam, take blood samples, and explain the procedure. Tests will be performed
           to check the donors heart, lung, kidney, and liver function.

        -  Donors will receive injections of a drug called filgrastim (G-CSF), which causes stem
           cells to travel from bone marrow into blood. The G-CSF shots will be given for 5 to 7
           days before the collection procedure.

        -  Donors will undergo apheresis to collect white blood cells and stem cells directly from
           the blood, which can be done as an outpatient procedure. Researchers may consider the
           alternative of directly collecting bone marrow from the donor, which will require an
           overnight hospital stay.

        -  Recipients:

        -  Recipients will receive 3 days of pre-transplant chemotherapy and radiation therapy to
           prepare for the transplant. For 4 days before the transplant, recipients will receive
           the chemotherapy drug fludarabine, followed by a single dose of radiation therapy, and
           will also receive the drugs tacrolimus and sirolimus to prevent the donor cells from
           attacking the recipient s normal tissues.

        -  Recipients will then receive the transplant of donor stem cells and will continue to
           receive tacrolimus and sirolimus for 3 months after the transplant to prevent the donor
           cells from attacking the recipient s normal tissues. Recipients will be discharged from
           the hospital once their condition is stable.

        -  Recipients will visit the NCI clinic regularly for the first 5 months after the
           transplant, and then less often for at least 5 years. Recipients may receive additional
           donor immune cells (donor lymphocyte infusion) after the transplant if the study doctors
           believe they are needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Mutations in GATA binding protein 2 (GATA2) lead to an immunodeficiency disease that
      transforms into myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). This
      syndrome, previously known as MonoMAC, has 4 clinical features: 1) infections with
      Mycobacterium Avium Complex (MAC) and other opportunistic infections as a teenager or young
      adult, 2) a peripheral blood leukocyte flow cytometry profile with T-lymphocytes, but a
      severe deficiency of monocytes, B-lymphocytes, and Natural Killer (NK) cells, 3) the
      propensity to progress to MDS/AML, and 4) mutations in the gene GATA2. In this pilot study we
      propose to evaluate the efficacy and safety of a reduced intensity allogeneic hematopoietic
      stem cell transplantation (HSCT) regimen for patients with mutations in GATA2. We are
      particularly interested in determining whether allogeneic HSCT using this regimen
      reconstitutes normal hematopoiesis in patients with mutations in GATA2.

      OBJECTIVES:

      Primary Objective:

        -  To determine efficacy, namely whether reduced-intensity allogeneic HSCT results in
           engraftment and restores normal hematopoiesis by day +100 in patients with mutations in
           GATA2.

        -  To determine the safety of this HSCT regimen in patients with mutations in GATA2,
           including transplant related toxicity, the incidence of acute and chronic graft-versus
           host disease, immune reconstitution, overall survival, and disease-free survival

      ELIGIBILITY:

      Eligibility includes patients 12-60 years old with mutations in GATA2 who have a life
      expectancy of &gt; 3 months but &lt; 24 months, and who have a 10/10 matched related donor, a 10/10
      or 9/10 matched unrelated donor (HLA -A, -B, -C, DRB1, DQB1 by high resolution typing
      identified through the National Marrow Donor Program), a 4/6 (or greater human leukocyte
      antigens (HLA -A), -B, DRB1) matched unrelated umbilical cord donor, or a haploidentical
      donor. Patients with GATA2 mutations who are 12-17 years of age are required to have MDS with
      chromosomal abnormalities to be eligible for this protocol.

      DESIGN:

        -  Patients with mutations in GATA2 with a 10/10 matched related or 10/10 matched unrelated
           donor, will receive a reduced-intensity pre-transplant conditioning regimen consisting
           of fludarabine 30 mg/m(2)/day on days -4, -3, and -2, 200 centigray (cGy) total body
           irradiation (TBI) on day -1, and HSCT on day 0. Patients with mutations in GATA2 and a
           9/10 matched unrelated donor will receive a reduced-intensity pre-transplant
           conditioning regimen consisting of fludarabine 30 mg/m(2)/day on days -4, -3, and -2,
           300cGy total body irradiation (TBI) on day -1, and HSCT on day 0. Patients with
           mutations in GATA2 with umbilical cord blood units will receive a reduced-intensity
           conditioning regimen with cyclophosphamide 50 mg/kg on day -6, fludarabine 40 mg/m(2) on
           days -6 to -2, equine anti-thymocyte globulin (ATG) 30 mg/kg intravenous (IV) on days
           -6, -5 and -4, 200 cGy TBI on day -1, and HSCT on day 0. Patients with a haploidentical
           donor will receive a reduced intensity-conditioning regimen with cyclophosphamide 14.5
           mg/kg on days -6 and -5, fludarabine 30 mg/m(2) on 4days -6 to -2, and 200 cGy TBI on
           day -1. Donor bone marrow cells will be infused on day 0.

        -  Post-transplant immunosuppression for graft-versus-host-disease prophylaxis will consist
           of sirolimus (Rapamycin) and tacrolimus until day +180, provided that there is no
           evidence of graft-versus-host disease. Post-transplant immunosuppression for graft
           versus-host-disease prophylaxis for recipients of haploidentical donors will consist of
           cyclophosphamide 50 mg/kg on days +3 and +4, along with sirolimus from day +5 to day
           180, and tacrolimus from day +5 to day 180, providing that there is no graft-versus-host
           disease (GVHD).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2009</start_date>
  <completion_date type="Actual">July 11, 2017</completion_date>
  <primary_completion_date type="Actual">June 12, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days to Neutrophil Engraftment</measure>
    <time_frame>30 days</time_frame>
    <description>Neutrophil engraftment is defined as a neutrophil count of &gt;0.5 x 10(9) cells/L for 3 consecutive days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days to Platelet Engraftment</measure>
    <time_frame>30 days</time_frame>
    <description>Platelet engraftment is defined as a platelet count of &gt;20 x 10(9) cells/L for 7 consecutive days without requiring a platelet transfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Donor Cells at Last Follow Up in Patients With Mutations GATA Binding Protein 2 (GATA2)</measure>
    <time_frame>2 years</time_frame>
    <description>Engraftment of donor cells was assessed using polymorphisms in regions known to contain short tandem repeats. Peripheral blood cluster of differentiation 14 (CD14+), cluster of differentiation 3 (CD3-)/cluster of differentiation 56 (CD56+), cluster of differentiation 19 (CD19+), and CD3+ subsets were isolated by flow cytometry and chimerism was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute and Chronic Graft-versus-host Disease (GVHD)</measure>
    <time_frame>2 years</time_frame>
    <description>Acute GVHD is assessed according to the 1994 Consensus Conference Grading Criteria. Chronic GVHD is assessed by the 2005 Chronic GVHD Consensus Project. GVHD can affect performance status and attack multiple organ systems such as the skin, liver, gut, mouth, eyes, joints, lung, etc. that can lead to a rash, diarrhea, metabolic changes, infection and/or death. The clinical grading of acute GVHD is grade 0 (none) to 4 (severe). Chronic GVHD is a delayed form of GVHD that may occur after day 100 post transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival is defined as date of on-study to date of death from any cause or last follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Disease Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants with documented evidence of disease progression following start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious and Non-serious Adverse Events</measure>
    <time_frame>91 months</time_frame>
    <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events v3.0. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>MDS</condition>
  <condition>Immunodeficiency</condition>
  <condition>GATA2</condition>
  <arm_group>
    <arm_group_label>Recipients and Healthy Related Donors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (CTX, Cytoxan)</intervention_name>
    <description>14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4</description>
    <arm_group_label>Recipients and Healthy Related Donors</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine(Fludara,Berlex Laboratories)</intervention_name>
    <description>40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2</description>
    <arm_group_label>Recipients and Healthy Related Donors</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Body Irradiation (TBI)</intervention_name>
    <description>200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)</description>
    <arm_group_label>Recipients and Healthy Related Donors</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell (HSC)</intervention_name>
    <description>stem cell transplant</description>
    <arm_group_label>Recipients and Healthy Related Donors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Equine Anti-Thymocyte Globulin</intervention_name>
    <description>30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)</description>
    <arm_group_label>Recipients and Healthy Related Donors</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA RECIPIENT:

               1. Patient age of 12-60 years

               2. GATA2 Mutation Syndrome

                    1. Clinical history of at least two episodes of life-threatening infection with
                       opportunistic organisms, one of which is a MAC infection.

                    2. Mutation in the GATA2 gene performed by the CLIA certified laboratory of Dr.
                       Steven Holland of the NIAID Institute of the NIH.

               3. Available 10/10 HLA-matched related or 8/8 matched unrelated donor, or 4/6 (or
                  greater) matched UCB unit(s) with a total dose of greater than or equal to 3.5
                  times 10(7) TNC/kg.

               4. Patients may have evidence of MDS with one or more peripheral blood cytopenias
                  and greater than 5% blasts but less than 10% blasts in the bone marrow in the
                  absence of GCSF.

                  Patients previously treated for acute myelogenous leukemia are eligible if they
                  have less than or equal to 10% blasts in the bone marrow in the absence of G-CSF.

                  Subjects 12-17 years of age are required to have MDS with chromosomal
                  abnormalities in addition to mutation in the GATA2 gene for enrollment on this
                  protocol.

               5. Left ventricular ejection fraction &gt; 50%, preferably by 2-D echo, or by MUGA, or
                  shortening fraction &gt; 28% by ECHO, obtained within 28 days of enrollment.

               6. Pulmonary Function Tests: Adult patients: DLCO diffusion capacity and FEV1
                  greater than 10% of expected value obtained within 28 days of enrollment.
                  Pediatric patients: DLCO corrected for hemoglobin and alveolar volume greater
                  than or equal to 20% of predicted.

               7. Creatinine: Adult patients: less than or equal to 2.0 mg/dl and creatinine
                  clearance greater than or equal to 30 ml/min; Pediatric patients: age-adjusted
                  normal serum creatinine OR a creatinine clearance &gt; 60 mL/min/1.73m(2).

               8. Serum total bilirubin less than 2.5 mg/dl; ALT and AST less than or equal to 5
                  times upper limit of normal .

               9. Adequate central venous access potential.

              10. Written informed consent/assent obtained from patient/parent or legal guardian.

              11. Life expectancy of at least 3 months but less than 24 months.

              12. Disease status: Patients are to be referred in remission for evaluation. Should a
                  patient have progressive disease or a donor not be available after enrollment,
                  the patient will be referred back to their primary hematologist-oncologist for
                  treatment. If this course of action is not in the best interest of the patient
                  according to the clinical judgment of the PI/LAI, then the patient may receive
                  standard treatment for the malignant disease under the current study. If under
                  either of these settings, it becomes apparent that the patient will not be able
                  to proceed to transplant, then he/she must come off study. Recipient-Subjects
                  receiving a standard therapy will be told about the therapy, associated risks,
                  benefits alternatives of the proposed therapy, and availability of receiving the
                  same treatment elsewhere, outside of a research protocol.

        EXCLUSION CRITERIA- RECIPIENT:

          1. HIV infection.

          2. Chronic active hepatitis B. Patient may be hepatitis B core antibody positive. For
             patients with a concomitant positive hepatitis B surface antigen, patients will
             require a hepatology consultation. The risk-benefit profile of transplant and
             hepatitis B will be discussed with the patient, and eligibility determined by the PI
             and the protocol chairperson.

          3. History of psychiatric disorder which may compromise compliance with transplant
             protocol, or which does not allow for appropriate informed consent.

          4. Active infection that is not responding to antimicrobial therapy.

          5. Active CNS involvement by malignancy (patients with known positive CSF cytology or
             parenchymal lesions visible by CT or MRI.

          6. Pregnant or lactating.

          7. Sexually active individuals capable of becoming pregnant who are unable or unwilling
             to use effective form(s) of contraception during time enrolled on study and for 1 year
             post-transplant. Effective forms of contraception include one or more of the
             following: intrauterine device (IUD), hormonal (birth control pills, injections, or
             implants), tubal ligation/hysterectomy, partners vasectomy, barrier methods, (condom,
             diaphragm, or cervical cap), or abstinence. The effects on breast-milk are also
             unknown and may be harmful to the infant; therefore, women should not breast feed
             during the interval from study entry to one year post-transplant. Males on the
             protocol must use an effective form of contraception at study entry, and for one year
             post-transplant. The effects of transplant, the radiation, and the medications used
             after transplant may be harmful to a fetus.

          8. Presence of active malignancy in another organ system other than the hematopoietic

          9. No available 10/10 HLA-matched related or 8/8 matched unrelated donor, or 4/6 (or
             greater) matched UCB unit(s) with a total dose of greater than or equal to 3.5 times
             10(7) TNC/kg.

         10. Lack of mutation in GATA2 as demonstrated by the CLIA certified laboratory of Dr.
             Steven Holland in the NIAID.

        INCLUSION CRITERIA- MATCHED RELATED DONOR:

          1. Related donor matched at HLA-A, B, C, DR, and DQ loci by high resolution typing (10/10
             antigen/allele match) are acceptable donors.

          2. Matched related donors for pediatric recipients must be 18 years of age or older. If
             more than one matched related donor is available, we will select the oldest donor to
             further decrease the risk of potential disease transmission.

          3. Ability to give informed consent.

          4. Age 18-60 years.

          5. No history of life-threatening opportunistic infection.

          6. Adequate venous access for peripheral apheresis, or consent to use a temporary central
             venous catheter for apheresis.

          7. Donors must be HIV negative, hepatitis B surface antigen negative, and hepatitis C
             antibody negative. This is to prevent the possible transmission of these infections to
             the recipient.

          8. A donor who is lactating must be willing and able to interrupt breast-feeding or
             substitute formula feeding for her infant during the period of filgrastim
             administration and for two days following the final dose. Filgrastim may be secreted
             in human milk, although its bioavailability from this source is not known. Limited
             clinical data suggest that short-term administration of filgrastim or sargramostim to
             neonates is not associated with adverse outcomes.

        INCLUSION CRITERIA- MATCHED UNRELATED DONOR:

          1. Unrelated donor matched at 10/10 or 9/10 HLA-A, B, C, DRB1, and DQB1 loci by high
             resolution typing.

          2. Matched unrelated donors for pediatric recipients must be 18 years of age or older.

          3. The evaluation of donors shall be in accordance with existing NMDP Standard Policies
             and Procedures. General donor inclusion criteria specified in the NMDP Standard.

        EXCLUSION CRITERIA- MATCHED RELATED DONOR:

          1. Age less than 18 years.

          2. HIV infection.

          3. Chronic active hepatitis B. Donor may be hepatitis core antibody positive.

          4. History of psychiatric disorder which in the opinion of the PI may compromise
             compliance with transplant protocol, or which does not allow to be appropriately
             informed.

          5. History of hypertension that is not controlled by medication, stroke, or severe heart
             disease. Individuals with symptomatic angina will be considered to have severe heart
             disease and will not be eligible to be a donor.

          6. Other medical contraindications to stem cell donation (i.e. severe atherosclerosis,
             autoimmune disease, iritis or episcleritis, deep venous thrombosis, cerebrovascular
             accident).

          7. History of prior malignancy. However, cancer survivors who have undergone potentially
             curative therapy may be considered for stem cell donation on a case-by-case basis. The
             risk/benefit of the transplant and the possibility of transmitting viable tumor cells
             at the time of transplantation will be discussed with the patient.

          8. Donors must not be pregnant. Pregnancy is an absolute contraindication under this
             protocol. The effects of cytokine administration on a fetus are unknown. Donors of
             childbearing potential must use an effective method of contraception. Effective forms
             of contraception include one or more of the following: intrauterine device (IUD),
             hormonal (birth control pills, injections, or implants), tubal ligation/hysterectomy,
             partner s vasectomy, barrier methods, (condom, diaphragm, or cervical cap), or
             abstinence.

          9. Thrombocytopenia (platelets less than 150,000 per micro l) at baseline evaluation.

         10. Donors receiving experimental therapy or investigational agents.

         11. Sensitivity to filgrastim or to E. coli-derived recombinant protein products.

         12. History of autoimmune disorders, with the exception of thyroid disorders.

         13. History of documented deep vein thrombosis or pulmonary embolism.

        EXCLUSION CRITERIA- MATCHED UNRELATED DONOR:

        Failure to qualify as an NMDP donor

        INCLUSION CRITERIA- UMBILICAL CORD BLOOD UNIT-HLA TYPING AND DOSE

          1. At least an HLA UCB 4/6 match (Class I-A, B by low resolution, and Class II-DR by high
             resolution) to recipient. The following algorithm will be applied to determine if
             patient will receive single or double umbilical cord graft:

          2. For Single UCB SCT:

               -  If 6/6 match the unit must have &gt; 3 x 10(7) nucleated cells /kg of recipient body
                  weight.

               -  If 5/6 match the unit must have &gt; 4 x 10(7) nucleated cells /kg of recipient body
                  weight.

               -  If 4/6 match the unit must have &gt; 5 x 10(7) nucleated cells/kg of recipient body
                  weight. Recipient body weight will be determined as per standard guidelines.

          3. If no single UCB with the above characteristics is available, a double UCB will be
             considered. Units will be selected with the following criteria:

               -  Both units will be at least 4/6 match (Class I-A, B by low resolution, Class
                  II-DR by high resolution) to recipient, and should be at least a 4/6 match (Class
                  I-A, B by low resolution, Class II-DR by high resolution) to each other.

               -  At least one UCB will have a minimum cell dose of 2.0 X 10(7) TNC/kg of recipient
                  body weight.

               -  The minimum combined dose of both units must be at least 3.5 x 10(7) TNC/kg of
                  recipient body weight.

               -  The smaller of the two units (UCB2) will have a minimum of 1.5 X 10(7) TNC/kg of
                  recipient body weight.

               -  The TNC of non-RBC reduced units will be dose corrected by -25% to allow for cell
                  loss while washing the unit.

        INCLUSION CRITERIA- HAPLOIDENTICAL RELATED DONOR:

          -  A haploidentical donor that shares one haplotype in common with the recipient such
             that HLA compatibility will be a minimum of 5 out of 10 HLA loci matched. The HLA loci
             to be tested will be HLA A, B, Cw, DRB1, and DQB1. A minimum number of mismatches is
             desirable; however if several options are available the selection of a donor will be
             based on the loci where the mismatch occurs and the relative importance of its
             potential immunological function. Donor-recipient pairs will initially be typed
             molecularly to provide a low resolution typing (antigen-level) to aid in the selection
             of the potential donor. Upon review of the familial inheritance pattern, a qualified
             HLA staff member will review haplotype inheritance. High resolution (allele-level)
             typing will be performed. Final selection of a donor will be in consultation with NCI
             physicians and qualified HLA personnel. Haploidentical related donors for pediatric
             recipients must be 15 years of age or older. If more than one haploidentical related
             donor is available, we will evaluate each donor individually according to overall
             health, ABO matching, cytomegalovirus (CMV), etc. to select the donor

          -  Age 15-60 years

          -  No history of life-threatening opportunistic infection

          -  Adequate venous access for peripheral apheresis, or consent to use a temporary central
             venous catheter for apheresis.

          -  Donors must be HIV negative, hepatitis B surface antigen negative, and hepatitis C
             antibody negative. This is to prevent the possible transmission of these infections to
             the recipient.

          -  Haploidentical donors will undergo marrow harvest with general anesthesia. Subjects
             will undergo anesthesia consultation, and meet criteria for eligibility/enrollment.
             CD34+ fraction will be determined.

          -  Subjects will also undergo the Donor Health History Screen to determine donor
             eligibility using standard DTM criteria in the Dowling Apheresis Clinic by skilled
             staff in the Blood Services Section for adult patients and age-appropriate questioning
             when indicated for pediatric subjects.

          -  Subjects will undergo follow-up history and physical examination within 1 week of
             donation.

        EXCLUSION CRITERIA- HAPLOIDENTICAL DONOR:

          -  Age less than 15 years.

          -  HIV infection

          -  Chronic active hepatitis B. Donor may be hepatitis core antibody positive.

          -  History of psychiatric disorder which in the opinion of the PI may compromise
             compliance with transplant protocol, or which does not allow for appropriate informed

          -  History of hypertension that is not controlled by medication, stroke, or severe heart
             disease. Individuals with symptomatic angina will be considered to have severe heart
             disease and will not be eligible to be a donor.

          -  Other medical contraindications to stem cell donation (i.e. severe atherosclerosis,
             autoimmune disease, iritis or episcleritis, deep venous thrombosis, cerebrovascular
             accident)

          -  History of prior malignancy. However, cancer survivors who have undergone potentially
             curative therapy may be considered for stem cell donation on a case-by-case basis. The
             risk/benefit of the transplant and the possibility of transmitting viable tumor cells
             at the time of transplantation will be discussed with the patient.

          -  Donors must not be pregnant. Pregnancy is an absolute contraindication under this
             protocol. The effects of cytokine administration on a fetus are unknown. Donors of
             childbearing potential must use an effective method of contraception. Effective forms
             of contraception include one or more of the following: intrauterine device (IUD),
             hormonal (birth control pills, injections, or implants), tubal ligation/hysterectomy,
             partners vasectomy, barrier methods, (condom, diaphragm, or cervical cap), or
             abstinence.

          -  Thrombocytopenia (platelets less than 150,000 per microliter) at baseline evaluation.

          -  Donors receiving experimental therapy or investigational agents.

          -  Sensitivity to filgrastim or to E. coli-derived recombinant protein products.

          -  History of autoimmune disorders, with the exception of thyroid disorders

          -  History of documented deep vein thrombosis or pulmonary embolism

          -  Mutation in GATA2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis D Hickstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2009-C-0096.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, Thomas ED, Hansen JA. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990 Oct;29(2):79-91.</citation>
    <PMID>2249952</PMID>
  </reference>
  <reference>
    <citation>Anderlini P, KÃ¶rbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, Howe C, Leitman S, Horowitz M, Gluckman E, Rowley S, Przepiorka D, Champlin R. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997 Aug 1;90(3):903-8.</citation>
    <PMID>9242518</PMID>
  </reference>
  <reference>
    <citation>Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 1;102(5):1601-5. Epub 2003 May 1.</citation>
    <PMID>12730113</PMID>
  </reference>
  <results_reference>
    <citation>Cuellar-Rodriguez J, Gea-Banacloche J, Freeman AF, Hsu AP, Zerbe CS, Calvo KR, Wilder J, Kurlander R, Olivier KN, Holland SM, Hickstein DD. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood. 2011 Sep 29;118(13):3715-20. doi: 10.1182/blood-2011-06-365049. Epub 2011 Aug 3.</citation>
    <PMID>21816832</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <results_first_submitted>May 3, 2017</results_first_submitted>
  <results_first_submitted_qc>October 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2017</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Dennis Hickstein, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>GATA2</keyword>
  <keyword>Transplant</keyword>
  <keyword>Immunodeficiency</keyword>
  <keyword>Myelodysplasia</keyword>
  <keyword>MonoMAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Recipients</title>
          <description>Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
Fludarabine(Fludara,Berlex Laboratories): 40 mg/m(2) intravenous (IV) (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
Total Body Irradiation (TBI): 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
Allogeneic hematopoietic stem cell (HSC): stem cell transplant</description>
        </group>
        <group group_id="P2">
          <title>Healthy Related Donors</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not go to transplant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data were not collected separately for donors and recipients.</population>
      <group_list>
        <group group_id="B1">
          <title>Recipients and Healthy Related Donors</title>
          <description>Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
Fludarabine(Fludara,Berlex Laboratories): 40 mg/m(2) intravenous (IV) (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
Total Body Irradiation (TBI): 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
Allogeneic hematopoietic stem cell (HSC): stem cell transplant Healthy related donors =5; recipients = 14.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.21" spread="7.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Days to Neutrophil Engraftment</title>
        <description>Neutrophil engraftment is defined as a neutrophil count of &gt;0.5 x 10(9) cells/L for 3 consecutive days.</description>
        <time_frame>30 days</time_frame>
        <population>10/19 analyzed:5 pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients Only</title>
            <description>Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
Fludarabine(Fludara,Berlex Laboratories): 40 mg/m(2) intravenous (IV) (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2 Total Body Irradiation (TBI): 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients) Allogeneic hematopoietic stem cell (HSC): stem cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Neutrophil Engraftment</title>
          <description>Neutrophil engraftment is defined as a neutrophil count of &gt;0.5 x 10(9) cells/L for 3 consecutive days.</description>
          <population>10/19 analyzed:5 pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="12" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Days to Platelet Engraftment</title>
        <description>Platelet engraftment is defined as a platelet count of &gt;20 x 10(9) cells/L for 7 consecutive days without requiring a platelet transfusion.</description>
        <time_frame>30 days</time_frame>
        <population>10/19 analyzed:5 pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients Only</title>
            <description>Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
Fludarabine(Fludara,Berlex Laboratories): 40 mg/m(2) intravenous (IV) (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2 Total Body Irradiation (TBI): 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients) Allogeneic hematopoietic stem cell (HSC): stem cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Platelet Engraftment</title>
          <description>Platelet engraftment is defined as a platelet count of &gt;20 x 10(9) cells/L for 7 consecutive days without requiring a platelet transfusion.</description>
          <population>10/19 analyzed:5 pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="0" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Donor Cells at Last Follow Up in Patients With Mutations GATA Binding Protein 2 (GATA2)</title>
        <description>Engraftment of donor cells was assessed using polymorphisms in regions known to contain short tandem repeats. Peripheral blood cluster of differentiation 14 (CD14+), cluster of differentiation 3 (CD3-)/cluster of differentiation 56 (CD56+), cluster of differentiation 19 (CD19+), and CD3+ subsets were isolated by flow cytometry and chimerism was assessed.</description>
        <time_frame>2 years</time_frame>
        <population>10/19 analyzed:5 pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients Only</title>
            <description>Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
Fludarabine(Fludara,Berlex Laboratories): 40 mg/m(2) intravenous (IV) (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2 Total Body Irradiation (TBI): 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients) Allogeneic hematopoietic stem cell (HSC): stem cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Donor Cells at Last Follow Up in Patients With Mutations GATA Binding Protein 2 (GATA2)</title>
          <description>Engraftment of donor cells was assessed using polymorphisms in regions known to contain short tandem repeats. Peripheral blood cluster of differentiation 14 (CD14+), cluster of differentiation 3 (CD3-)/cluster of differentiation 56 (CD56+), cluster of differentiation 19 (CD19+), and CD3+ subsets were isolated by flow cytometry and chimerism was assessed.</description>
          <population>10/19 analyzed:5 pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Donor CD14+ cells, %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Donor CD19+ cells, %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Donor CD3-/CD56+ cells, %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Donor CD3+ cells, %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Acute and Chronic Graft-versus-host Disease (GVHD)</title>
        <description>Acute GVHD is assessed according to the 1994 Consensus Conference Grading Criteria. Chronic GVHD is assessed by the 2005 Chronic GVHD Consensus Project. GVHD can affect performance status and attack multiple organ systems such as the skin, liver, gut, mouth, eyes, joints, lung, etc. that can lead to a rash, diarrhea, metabolic changes, infection and/or death. The clinical grading of acute GVHD is grade 0 (none) to 4 (severe). Chronic GVHD is a delayed form of GVHD that may occur after day 100 post transplant.</description>
        <time_frame>2 years</time_frame>
        <population>10/19 analyzed:5 pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients Only</title>
            <description>Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
Fludarabine(Fludara,Berlex Laboratories): 40 mg/m(2) intravenous (IV) (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2 Total Body Irradiation (TBI): 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients) Allogeneic hematopoietic stem cell (HSC): stem cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute and Chronic Graft-versus-host Disease (GVHD)</title>
          <description>Acute GVHD is assessed according to the 1994 Consensus Conference Grading Criteria. Chronic GVHD is assessed by the 2005 Chronic GVHD Consensus Project. GVHD can affect performance status and attack multiple organ systems such as the skin, liver, gut, mouth, eyes, joints, lung, etc. that can lead to a rash, diarrhea, metabolic changes, infection and/or death. The clinical grading of acute GVHD is grade 0 (none) to 4 (severe). Chronic GVHD is a delayed form of GVHD that may occur after day 100 post transplant.</description>
          <population>10/19 analyzed:5 pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as date of on-study to date of death from any cause or last follow up.</description>
        <time_frame>2 years</time_frame>
        <population>10/19 analyzed:5 pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients Only</title>
            <description>Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
Fludarabine(Fludara,Berlex Laboratories): 40 mg/m(2) intravenous (IV) (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2 Total Body Irradiation (TBI): 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients) Allogeneic hematopoietic stem cell (HSC): stem cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as date of on-study to date of death from any cause or last follow up.</description>
          <population>10/19 analyzed:5 pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="18" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Disease Free Survival</title>
        <description>Number of participants with documented evidence of disease progression following start of treatment.</description>
        <time_frame>2 years</time_frame>
        <population>10/19 analyzed:5pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients Only</title>
            <description>Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
Fludarabine(Fludara,Berlex Laboratories): 40 mg/m(2) intravenous (IV) (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2 Total Body Irradiation (TBI): 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients) Allogeneic hematopoietic stem cell (HSC): stem cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Disease Free Survival</title>
          <description>Number of participants with documented evidence of disease progression following start of treatment.</description>
          <population>10/19 analyzed:5pts were healthy related donors, 1 pt taken off study prior to transplant &amp; 3 pts had early deaths (before outcome measurements could be evaluated)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious and Non-serious Adverse Events</title>
        <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events v3.0. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>91 months</time_frame>
        <population>Data were not collected separately for donors and recipients.</population>
        <group_list>
          <group group_id="O1">
            <title>Recipients and Healthy Related Donors</title>
            <description>Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
Fludarabine(Fludara,Berlex Laboratories): 40 mg/m(2) intravenous (IV) (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2 Total Body Irradiation (TBI): 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients) Allogeneic hematopoietic stem cell (HSC): stem cell transplant Healthy related donors =5; recipients = 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-serious Adverse Events</title>
          <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events v3.0. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <population>Data were not collected separately for donors and recipients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>91 months</time_frame>
      <desc>Data were not collected separately for donors and recipients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Recipients and Healthy Related Donors</title>
          <description>Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
Fludarabine(Fludara,Berlex Laboratories): 40 mg/m(2) intravenous (IV) (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2 Total Body Irradiation (TBI): 200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients) Allogeneic hematopoietic stem cell (HSC): stem cell transplant Healthy related donors =5; recipients = 14.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac troponin I (cTnI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest, cause unknown (non-fatal)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI::Upper GI NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)::Stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic)::Esophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic)::Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term::Death NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hepatobiliary/Pancreas - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection)(ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>(documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Blood</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Gallbladder (cholecystitis)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Sinus</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>(documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Urinary tract NOS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Upper aerodigestive NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Upper airway NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Leak (including anastomotic), GI::Leak NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU::Vagina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory::Lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DIC (disseminated intravascular coagulation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vessel injury-artery::Other NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>CD4 count</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="72" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="90" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphedema-related fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="126" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Lymph node</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="37" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia - Other (Specify, persistent tachycardia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Prolonged QTc interval</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia::Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia::Sinus tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing: patients without baseline audiogram and not enrolled in a monitoring program</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ocular surface disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ocular/Visual - Other (Specify, decreased vision)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites (non-malignant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Enteritis (inflammation of the small bowel)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify, v)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI::Lower GI NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)::Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic)::Oral cavity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Anus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Dental/teeth/peridontal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other (Specify, diathesis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Pain NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure (clinical)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection)(ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="11" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Blood</description>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Catheter-related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Pharynx</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Pleura (empyema)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Rectum</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Spinal cord (myelitis)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Urinary tract NOS</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Vagina</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically)</sub_title>
                <description>with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)::Wound</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection - Other (Specify, skin:zoster; thrush)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Anal/perianal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Bladder (urinary)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Blood</sub_title>
                <counts group_id="E1" events="21" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Catheter-related</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Ileum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Larynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Nose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Oral cavity-gums (gingivitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Peritoneal cavity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Pharynx</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Sinus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Skin (cellulitis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Upper aerodigestive NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Upper airway NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Urinary tract NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Vulva</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Wound</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Blood</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Brain + Spinal cord (encephalomyelitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Bronchus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Catheter-related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Upper airway NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="37" subjects_affected="11" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="38" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Acidosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="23" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholesteremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>GGT (gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="48" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemolysis (e.g., immune hemolytic anemia, drug-related hemolysis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="23" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum-high (hypertriglyceridemia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain::Bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy)::Facial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Bone</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Extremity-limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy - possibly related to cancer treatment (Specify, donor cell leukemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain::Head/headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Leak, cerebrospinal fluid (CSF)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mood alteration::Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Head/headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain::Testicle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vaginal stenosis/length</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusion capacity (DL(co))</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>FEV(1)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory::Nose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal change lymphedema, phlebolymphedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify, v dermatitis per biopsy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain::Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Urticaria (hives, welts, wheals)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy (e.g., thrombotic thrombocytopenic purpura [TTP]</sub_title>
                <description>or hemolytic uremic syndrome [HUS])</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dennis Hickstein</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-594-1718</phone>
      <email>hicksted@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

